Are financial incentives cost-effective to support smoking cessation during pregnancy?

Addiction

Volumn 111, Issue 2, 2016, Pages 360-370

  Boyd, Kathleen A ^a   Briggs, Andrew H ^a   Bauld, Linda ^b   Sinclair, Lesley ^b   Tappin, David ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UK CENTRE FOR TOBACCO AND ALCOHOL STUDIES   (United Kingdom)

Author keywords

Cost effectiveness; Financial incentives; Pregnancy; Smoking cessation

Indexed keywords

CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH PROMOTION; HUMAN; MARKOV CHAIN; MOTIVATION; PHASE 2 CLINICAL TRIAL; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; PREVENTION AND CONTROL; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SCOTLAND; SMOKING; SMOKING CESSATION;

COST-BENEFIT ANALYSIS; FEMALE; HEALTH PROMOTION; HUMANS; MARKOV CHAINS; MOTIVATION; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; QUALITY-ADJUSTED LIFE YEARS; SCOTLAND; SMOKING; SMOKING CESSATION;

EID: 84954393093     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13160     Document Type: Article

References (72)

1. Lowry C., Scammell K. Smoking Cessation in Pregnancy: A Call to Action. London: Action on Smoking and Health (ASH), Royal College of Nursing; 2013. ISBN: 978-1-872428-92-5.
2. World Health Organization (WHO) WHO Recommendations for the Prevention and Management of Tobacco Use and Second-Hand Smoke Exposure in Pregnancy. Geneva: WHO; 2013.
3. Godfrey C., Pickett K., Parrott S., Mdege N., Eapen P. Estimating the Costs to the NHS of Smoking in Pregnancy for Pregnant Women and InfantsFinal report. York: Public Health Research Consortium, University of York; 2010.
4. Adams E., Miller V., Ernst C., Nishimura B., Melvin C., Merritt R. Neonatal health care costs related to smoking during pregnancy. Health Econ 2002; 11: 193-206.
5. American Lung Association Facts and Figures: Women and Tobacco Use. American Lung Association; USA, 2015.
6. World Health Organization (WHO). WHO Report on the Global Tobacco Epidemic 2009: Implementing Smoke-Free Environments. Geneva, Switzerland; 2009.
7. European Medicines Agency Guideline on the Development of Medicinal Products for the Treatment of Smoking. London, UK: European Medicines Agency; 2008.
8. Information Services Division Births in Scottish Hospitals: year ending 31st March 2013; Information Services Division, Scotland; 2014.
9. Tappin D., MacAskill S., Bauld L., Eadie D., Shipton D., Galbraith L. Smoking prevalence and smoking cessation services for pregnant women in Scotland. Subst AbuseTreat Prev Policy 2010; 5(1):1-10.
10. Bauld L., Coleman T. The Effectiveness of Smoking Cessation Interventions During Pregnancy: A Briefing Paper. National Institute for Health and Clinical Excellence: London, UK; 2009.
11. National Institute for Health and Clinical Excellence Quitting Smoking in Pregnancy and Following Childbirth. London, UK: National Institute for Health and Clinical Excellence; 2010.
12. Bostock Y. Searching for the Solution: Women, Smoking and Inequalities in Europe. London, UK: Health Development Agency, NHS; 2003.
13. Volpp K., Troxel A., Pauly M., Glick H., Puig A., Asch D. et al. A randomized controlled trial of financial incentives for smoking cessation. N Engl J Med 2009; 360: 699-709.
14. Giles E., Robalino S., McColl E., Sniehotta F., Adams J. The effectiveness of financial incentives for health behaviour change: systematic review and meta-analysis. PLOS ONE 2014; 9e90347.
15. Higgins S. T., Silverman K., Heil S. Contingency Management in Substance Abuse Treatment. New York: Guilford Press; 2008.
16. Higgins S. T. Comments on contingency management and conditional cash transfers. Health Econ 2010; 19: 1255-8.
17. Lussier J., Heil S., Mongeon J., Badger G., Higgins S. T. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006; 101: 192-203.
18. Grand J., Titmuss R., Srivastava D. Incentives for Prevention. Report no. 3 London, UK: Health England; 2009.
19. Pilling S., Strang J., Gerada C. Psychosocial interventions and opioid detoxification for drug misuse: summary of NICE guidelines. BMJ 2007; 2007: 203-5.
20. Higgins S. T., Washio Y., Heil S. Financial incentives for smoking cessation among pregnant and newly postpartum women. Prev Med 2012; 55(Suppl.): S33-40.
21. Hoddinott P., Morgan H., MacLennan G., Sewel K., Thomson G., Bauld L. et al. Public acceptability of financial incentives for smoking cessation in pregnancy and breast feeding: a survey of the British public. BMJ Open 2014; 4e005524.
22. Lumley J., Oliver S., Chamberlain C., Oakley L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2009; 3CD001055: .
23. Coleman T., Cooper S., Thornton J., Grainge M., Watts K., Britton J. et al. A randomized trial of nicotine-replacement therapy patches in pregnancy. N Engl J Med 2012; 366: 808-18.
24. Coleman T., McEwen A., Bauld L., Ferguson J., Lorgelly P., Lewis S. Protocol for the Proactive Or Reactive Telephone Smoking Cessation Support (PORTSSS) trial. Trials 2009; 10: 1-12.
25. Higgins S. T., Washio Y., Lopez A., Heil S., Solomon L., Lynch M. et al. Examining two different schedules of financial incentives for smoking cessation among pregnant woment. Prev Med 2014; 68: 51-7.
26. Ierfino D., Mantzari E., Hirst J., Jones T., Aveyard P., Marteau T. Financial incentives for smoking cessation in pregnancy: a single-arm intervention stuidy assessing cessation and gaming. Addiction 2015; 110: 680-8.
27. Tuten M., Fitzsimmons H., Chisolm M., Nuzzo P., Jones H. Contingent incentives reduce cigarette smoking in pregnant, methodone-maintained women: results of an initial feasibility and efficacy randomized controlled trial. Addiction 2012; 107: 1868-77.
28. Schlander M. Health Technology Assessments by the National Institute for Health Clinical Excellence: a Qualitative Study. New York: Springer; 2007.
29. National Institute for Health and Care Excellence (NICE) NICE: What We Do. London, UK: NICE; 2014.
30. National Institute for Health and Care Excellence (NICE) Guide to the Methods of Technology Appraisal: 2013. London, UK: NICE; 2013.
31. Hutton J., McGarth C., Frybourg J., Tremblay M., Bramley-Harker E., Henshall C. Framework for describing and classifying decision-making systems using technology assessment to determine the reimbursement of health technologies (fourth hurdle systems. Int J Technol Assess Health Care 2006; 22: 10-18.
32. Tappin D., Bauld L., Tannahill C., De Caestecker L., Radley A., McConnachie A. et al. The Cessation in Pregnancy Incentives Trial (CPIT): study protocol for a randomised controlled trial. Trials 2012; 13: 113.
33. Tappin D., Bauld L., Boyd K. A., Sinclair L., MacAskill S., McKell J. et al. Financial incentives for smoking cessation in pregnancy (CPIT): randomised controlled trial. BMJ 2015; 350: h134.
34. Tappin D., Bauld L., Purves D., Boyd K., Sinclair L., MacAskill S. et al. Financial incentives for smoking cessation during pregnancy: a randomised controlled trial. Lancet 2014; 384: S4.
35. Petrou S., Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ 2011; 342: 1069-73.
36. Boyd K. A., Briggs A. H. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction 2009; 104: 317-325.
37. Bauld L., Boyd K. A., Briggs A. H., Chesterman J., Ferguson J., Judge K. et al. One year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led treatment services. Nicotine Tob Res 2011; 13: 135-45.
38. British National Formulary British National Formulary 66. London, UK: Pharmaceutical Press; 2013.
39. Curtis L. Unit Costs of Health and Social Care 2012. Canterbury: University of Kent at Canterbury, PSSRU; 2012.
40. Briggs A. H. Handling uncertainty in economic evaluations and presenting the results. In: Drummond M., McGuire A., editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001, pp. 172-214.
41. Fenwick E., Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychol 2005; 187: 108.
42. Fenwick E., Palmer S., Claxton K., Sculpher M., Abrams K., Sutton A. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery. Med Decis Making 2006; 26: 480-96.
43. Lussier J., Heil S., Mongeon J., Badger G., Higgins S. T. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006; 101: 192-203.
44. Higgins S. T., Bernstein I., Washio Y., Heil S., Badger G., Skelly J. et al. Effects of smoking cessation with voucher-based contingency management on birth outcomes. Addiction 2010; 105: 2023-30.
45. Godfrey C., Parrott S., Coleman T., Pound E. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 2005; 100: 70-83.
46. Owen L., Morgan A., Fischer A., Ellis S., Hoy A., Kelly M. The cost-effectiveness of public health interventions. J Public Health 2011; 34: 37-45.
47. Dallat M., Hunter R., Tully M., Cairns K., Kee F. A lesson in business: cost-effectiveness analysis of a novel financial incentive intervention for increasing physical activity in the workplace. BMC Public Health 2013; 13: 953.
48. Higgins S. T. A larger context for considering the Tappin et al. report on financial incentives for smoking cessation in pregnant and newly postpartum women. BMJ 2015; 350: h134.
49. Menon D., Stafinski T. Health Technology Assessment in Canada: 20 Years Strong? Value Health 2009; 12: S14-19.
50. Marseille E., Larson B., Kazi D., Kahn J., Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 2015; 93: 118-24.
51. Hoogendoorn M., Welsing P., Rutten-van Molken M. P., Hoogendoorn M., Welsing P., Rutten-Van Molken M. P. M. H. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008; 24: 51-61.
52. Chen F., Madan J., Welton N., Yahaya I., Aveyard P., Bauld L., et al. Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis. Health Technol Assess 2012; 16(38): 1-205.
53. Cooper S., Lewis S., Thornton J., Marlow N., Watts K., Britton J. et al. The SNAP trial: a randomised placebo-controlled trial of nicotine replacement therapy in pregnancy-clinical effectiveness and safety until 2 years after delivery, with economic evaluation. Health Technol Assess 2014; 18(54): 1-160.
54. Dornelas E., Magnavita J., Beazoglou T., Fischer E., Oncken C., Lando H. et al. Efficacy and cost-effectiveness of a clinic-based counseling intervention tested in an ethnically diverse sample of pregnant smokers. Patient Ed Counsel 2006; 64: 342-9.
55. Ruger J. P., Emmons K. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review. Value Health 2008; 11: 180-90.
56. Marteau T., Thorne J., Aveyard P., Hirst J., Sokal R. Financial incentives for smoking cessation in pregnancy: protocol for a single arm intervention study. BMC Pregnancy Childbirth 2013; 13: 66.
57. Batech M., Tonstad S., Job J., Chinnock R., Oshiro B., Merritt T. et al. Estimating the impact of smoking cessation during pregnancy: the San Bernardino County experience. J Community Health 2013; 38: 838-46.
58. Information Services Division. NHS Smoking Cessation Services Scotland: 1st January to 31st December 2014. Information Services Division, Scotland; 2015.
59. Chamberlain C., O'Mara-Eves A., Oliver S. et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev 2013; 10: 1-349.
60. Berlin I., Grange G., Jacob N., Tanguy M. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ 2014; 348: g1622.
61. Likis F., Andrews J., Fonnesbeck C., Hartmann K., Jerome R., Potter S. et al. Smoking Cessation Interventions in Pregnancy and Postpartum Care. Evidence Report Number 214. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
62. ASH Scotland Smoking and Tobacco Statistics Fact Sheet. Edinburgh: ASH Scotland; 2014.
63. Cahill K., Perara R. Competitions and incentives for smoking cessation. Cochrane Database Syst Rev 2011;4: 1-53.
64. Donatelle R., Prows S., Champeau D., Hudson D. Randomised controlled trial using social support and financial incentives for high risk pregnant smokers: Significant Other Supporter (SOS) program. Tob Control 2000; 9: 67-9.
65. Yudkin P., Hey K., Roberts S., Welch S., Murphy M., Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. BMJ 2003; 327: 28-9.
66. British National Formulary (BNF) BNF 65. London, UK: Pharmaceutical Press; 2012.
67. Information Services Division. Scottish Health Service Costs Book 2012. Scotland: Information Services Division; 2012.
68. ASH Scotland Up in Smoke: The Economic Cost of Tobacco in Scotland. Edinburgh: ASH Scotland; 2010.
69. General Register Office for Scotland Vital Events Reference Tables 2012: Deaths-Table 5.1b, Age sex death rates. Edinburgh: General Register Office for Scotland; 2013.
70. Peto R., Lopez A., Boreham J., Thun M. Mortality from smoking in developed countries 1950-2005 (or later): Scotland: University of Oxford, UK; 2012.
71. Kind P., Hardman G., Macran S. UK Population Norms for EQ-5D. Discussion Paper 172. York: Centre for Health Economics, University of York; 1999.
72. Stapleton J. A., West R. A direct method and ICER tables for the estimation of the cost-effectiveness of smoking cessation interventions in general populations: application to a new cytisine trial and other examples. Nicotine Tob Res 2012; 14: 463-71.